Hikma has extended its partnership with Celltrion for biosimilars in the Middle East and North Africa region with an exclusive licensing deal that will add the Korean firm’s Remsima SC (infliximab) subcutaneous formulation to Hikma’s MENA portfolio.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?